Dr. Chawla joined Acer as Vice President, Medical Director in September 2021. She brings to Acer over 20 years of biopharmaceutical industry experience. As a scientist, Dr. Chawla has worked in the development and optimization of drug-binding and cell-based assays and the purification of proteins. As a clinician, she has worked in the therapeutic areas of oncology, hematology, and metabolic disorders. Dr. Chawla has served as a key team member for an FDA Advisory Committee Meeting, led clinical development programs, and been responsible for the safety profile of numerous compounds in Phase 2 and Phase 3 studies. Prior to Acer, Dr. Chawla held various roles of increasing responsibilities at Fibrogen, SFJ Pharmaceuticals, Onyx, and BioMarin. She received a B.S. degree in Biochemistry from the University of California Davis and an M.D. from American University of the Caribbean.
